Zymeworks (ZYME) Free Cash Flow (2021 - 2026)
Zymeworks (ZYME) reported Free Cash Flow of -$45.8 million for Q1 2026, down 1238.53% on a YoY basis from $4.0 million in Q1 2025, and down 322.68% sequentially from -$10.8 million in Q4 2025.
Zymeworks (ZYME) Free Cash Flow (2021 - 2026) Analysis & Trends
Zymeworks (ZYME) has 6 years of Free Cash Flow data on file, last reported at -$45.8 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 1238.53% year-over-year to -$45.8 million; the trailing twelve-month figure through Mar 2026 stood at -$76.9 million (up 1.13% YoY), and the FY2025 full-year result was -$34.5 million, up 69.19% from the prior year.
- Free Cash Flow fell to -$45.8 million in Q1 2026, from -$10.8 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $327.8 million in Q4 2022 to a low of -$83.6 million in Q1 2023.
- A 5-year average of -$9.9 million and a median of -$31.8 million in 2025 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow surged 745.43% in 2022 and tumbled 1238.53% in 2026, its largest moves.
- Tracing ZYME's Free Cash Flow over 5 years: stood at $327.8 million in 2022, then slumped by 95.14% to $15.9 million in 2023, then tumbled by 362.57% to -$41.8 million in 2024, then surged by 74.08% to -$10.8 million in 2025, then slumped by 322.68% to -$45.8 million in 2026.
- Business Quant data shows ZYME's Free Cash Flow at -$45.8 million in Q1 2026, -$10.8 million in Q4 2025, and -$31.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.95 Mn |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | -45.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.82 Mn |
| Mar 31, 2026 | -45.82 Mn |
| Dec 31, 2025 | -10.84 Mn |
| Dec 31, 2025 | -10.84 Mn |
| Sep 30, 2025 | -31.82 Mn |
| Sep 30, 2025 | -31.82 Mn |
| Jun 30, 2025 | 11.56 Mn |
| Jun 30, 2025 | 11.56 Mn |
| Mar 31, 2025 | -3.42 Mn |
| Mar 31, 2025 | -3.42 Mn |
| Dec 31, 2024 | -41.82 Mn |
| Dec 31, 2024 | -41.82 Mn |
| Sep 30, 2024 | -6.78 Mn |
| Sep 30, 2024 | -6.78 Mn |
| Jun 30, 2024 | -25.77 Mn |
| Jun 30, 2024 | -25.77 Mn |
| Mar 31, 2024 | -37.68 Mn |
| Mar 31, 2024 | -37.68 Mn |
| Dec 31, 2023 | 15.93 Mn |
| Dec 31, 2023 | 15.93 Mn |